Conditions: Social Anxiety Disorder
Keywords: anxiety disorder SAD ziprasidone sertraline antidepressant antipsychotic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone

Detailed description:
This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.

Arms:
arm 1: 8 weeks of open label treatment with sertraline arm 2: 8 weeks of treatment with sertraline augmented with ziprasidone arm 3: 8 weeks of treatment with sertraline augmented by placebo

Interventions: intervention 1: Ziprasidone intervention 2: Sertraline
Intervention descriptions: intervention 1: Sertraline augmentation with ziprasidone intervention 2: Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase

Protocol document: